Amylyx's Avexitide Shows 55% Reduction in Hypoglycemic Events in Phase 3 Trial
Event summary
- Amylyx's Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) met primary endpoint, showing 55% reduction in hypoglycemic events vs. placebo (p=0.000003).
- All secondary endpoints were met, including reductions in Level 2 and Level 3 hypoglycemic events measured by SMBG, CGM, and adjudication.
- Avexitide was well-tolerated with no serious adverse events related to treatment; most common side effects were mild to moderate.
- Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026, with potential commercial launch in 2027 if approved.
The big picture
Amylyx's positive Phase 3 results for avexitide address a critical gap in treating post-bariatric hypoglycemia, a condition affecting ~8% of bariatric surgery patients in the U.S. The data strengthen Amylyx's position in the endocrine space, particularly as GLP-1-based therapies gain traction. The company's planned NDA submission by year-end 2026 could position it as a first-mover in this niche but significant indication.
What we're watching
- Regulatory Pathway
- Whether the FDA will expedite review given the Breakthrough Therapy Designation and the urgent unmet need in PBH.
- Market Potential
- The pace at which Amylyx can scale commercialization if avexitide gains approval, targeting ~160,000 U.S. patients with PBH.
- Competitive Landscape
- How this success positions Amylyx in the broader endocrine and metabolic disease space, particularly against GLP-1-focused therapies.